UniProtKB/Swiss-Prot P02647 : Variant p.Ala199Pro
Apolipoprotein A-I
Gene: APOA1
Feedback ?
Variant information
Variant position:
199
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:
US
The variants are classified into three categories: LP/P, LB/B and US.LP/P: likely pathogenic or pathogenic. LB/B: likely benign or benign. US: uncertain significance
Residue change:
From Alanine (A) to Proline (P) at position 199 (A199P, p.Ala199Pro).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:
Change from small size and hydrophobic (A) to medium size and hydrophobic (P)
The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:
-1
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another: Lowest score: -4 (low probability of substitution).Highest score: 11 (high probability of substitution). More information can be found on the following page
Variant description:
In AMYLD3; uncertain significance.
Any additional useful information about the variant.
Sequence information
Variant position:
199
The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:
267
The length of the canonical sequence.
Location on the sequence:
HVDALRTHLAPYSDELRQRL
A ARLEALKENGGARLAEYHAK
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:
The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human HVDALRTHLAPYSDELRQRLA ARLEALKENGGARLAEYHAK
Gorilla HVDALRTHLAPYSDELRQRLA ARLEALKENGGARLAEYHAK
HVDALRAQLAPYSDDLRERLA ARLEALKEGGGASLAEYHAR
Rhesus macaque HVDALRTHLAPYSDELRQRLA ARLEALKENGGARLAEYHAK
Chimpanzee HVDALRTHLAPYSDELRQRLA ARLEALKENGGARLAEYHAK
Mouse HVDSLRTQLAPHSEQMRESLA QRLAELKSN--PTLNEYHTR
Rat NADALRAKFGLYSDQMRENLA QRLTEIKNH--PTLIEYHTK
Pig HVEALRQHVAPYSDDLRQRMA ARFEALKEGGGS-LAEYQAK
Bovine HVETLRQQLAPYSDDLRQRLT ARLEALKEGGGS-LAEYHAK
Rabbit HVDTLRTKLAPYSNELQQRLA ARLESIKEGGGASLAEYQAK
Chicken HVEELRKNLAPYSDELRQKLS QKLEEIREKGIPQASEYQAK
Zebrafish NIEETKSKVVPMVEAVRTKLT ERLEDLRTMAAPYAEEYKEQ
Sequence annotation in neighborhood:
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
19 – 267
Proapolipoprotein A-I
Chain
25 – 267
Apolipoprotein A-I
Chain
25 – 266
Truncated apolipoprotein A-I
Repeat
189 – 210
7
Region
68 – 267
10 X approximate tandem repeats
Modified residue
190 – 190
3'-chlorotyrosine; alternate
Modified residue
190 – 190
3'-nitrotyrosine; alternate
Modified residue
216 – 216
3'-chlorotyrosine; alternate
Modified residue
216 – 216
3'-nitrotyrosine; alternate
Mutagenesis
190 – 190
Y -> F. Abolished chlorination and nitration without preventing inhibition in presence of myeloproxidase; when associated with F-42, F-53, F-124, F-139, F-216 and F-260.
Mutagenesis
216 – 216
Y -> F. Abolished chlorination and nitration without preventing inhibition in presence of myeloproxidase; when associated with F-42, F-53, F-124, F-139, F-190 and F-260.
Helix
166 – 203
Literature citations
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis.
Lachmann H.J.; Booth D.R.; Booth S.E.; Bybee A.; Gilbertson J.A.; Gillmore J.D.; Pepys M.B.; Hawkins P.N.;
N. Engl. J. Med. 346:1786-1791(2002)
Cited for: VARIANTS AMYLD3 ARG-50 AND PRO-199; INVOLVEMENT IN AMYLD3;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.